Hello, and welcome to the Transgene First-Half 2023 Financial Results and Business Update Call. Please note this conference is being recorded and for the duration of the call your lines will be on ...
TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Transgene a annoncé la nomination de deux nouveaux conseillers scientifiques de premier plan au sein de son Conseil Scientifique, le Professeur Antoine Italiano, MD, PhD, et le Professeur Ignacio ...
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet ...
Transgene's intravenous IL-12-armed oncolytic virus TG-6050 cleared to enter clinic trials in France
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital. So it seems the smart money knows that debt - which is ...
Good day, and thank you for standing by. Welcome to the Transgene 2025 Half Year Financial Results Conference Call and Webcast. [Operator Instructions] After the speaker's presentation, there will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results